XNAS
ISPC
Market cap352kUSD
Jul 09, Last price
2.54USD
1D
10.92%
1Q
-50.43%
IPO
-99.96%
Name
iSpecimen Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||